Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its investigational drug JAB-23E73, a pan-KRAS inhibitor developed in-house. This follows prior clearance from U.S. authorities to initiate a Phase I/IIa study for the drug in patients with advanced solid tumors.
Globally, approximately 2.7 million new cancer patients with KRAS-related mutations each year are anticipated to benefit from pan-KRAS inhibitors. JAB-23E73 is capable of simultaneously inhibiting both active and inactive forms of KRAS, which are prevalent in various tumor mutations, without significantly affecting HRAS and NRAS. The oral KRAS inhibitor has demonstrated favorable pharmacokinetic properties in preclinical trials.- Flcube.com
